Results for tag: "Ataxia Telangiectasia Drug"

Ataxia Telangiectasia (A-T) is a rare, genetic disorder that affects the central nervous system. It is characterized by progressive neurological deterioration, immunodeficiency, and increased risk of cancer. The Ataxia Telangiectasia Drug market is focused on developing treatments to improve the quality of life of those affected by the disorder. These treatments include drugs that target the underlying genetic defect, as well as drugs that target the symptoms of the disorder. The Ataxia Telangiectasia Drug market is highly competitive, with many companies developing treatments for the disorder. Some of the major players in the market include GlaxoSmithKline, Novartis, Pfizer, and Sanofi. Other companies involved in the development of treatments for A-T include AbbVie, AstraZeneca, and Merck. Show Less Read more